BLSM Stock Forecast & Price Target

BlossomHill Therapeutics is favored because BH-30643 is generating encouraging Phase 1 activity in heavily pretreated EGFR-mutant NSCLC, including 53% partial responses in C797S+ patients without prior chemotherapy and 78% responses in TKI-naive classical EGFR+ patients, while showing broad mutation coverage, CNS activity, and a comparatively favorable safety profile. The company also has multiple shots on goal: BH-30236 showed 28.6% marrow blast reductions on monotherapy and 36% ORR in R/R AML, while BH-501284 adds preclinical KRAS optionality, all supported by a management team with a strong oncology development track record. Financially, BlossomHill ended 2Q26 with $95 million in cash and equivalents plus $168 million of IPO proceeds, implying a runway into 2Q28 and enough capital to reach important data and pivotal milestones without immediate financing pressure.

BlossomHill Therapeutics is viewed negatively because it remains a pre-profit clinical-stage company with no approved products, projected diluted net losses per share of $3.71 in 2026 and $2.99 in 2027, and a need for continued capital despite $253.6 million in pro forma cash that only funds operations into at least 2Q28. Its valuation hinges heavily on BH-30643, yet the program still faces meaningful execution, regulatory, and commercialization risk, while safety concerns such as 7.1% grade ≥3 ALT elevations, 4.6% AST elevations, and 1.0% pneumonitis could constrain adoption. The rest of the pipeline adds limited near-term de-risking because BH-30236 and BH-501284 remain earlier-stage, and the company must compete against larger, entrenched oncology players in crowded markets with uncertain market access and possible dilution.